Platform of Novel Peptides to inhibit MARCKS
MARCKS is an intracellular protein with an essential role in the regulation of inflammation, cell motility, and secretion. As a critical component of the inflammatory process, MARCKS is responsible for neutrophil aggregation at the site of inflammation and cytokine release. MARCKS is also implicated in the development of certain cancers.
BIO-11006 is a novel peptide that inhibits the MARCKS protein. It is part of a portfolio of over 100 patented compounds owned by Biomarck. Phase 2 clinical trials have been completed with BIO-11006 in ARDS, COPD, and NSCLC. Biomarck is also investigating BIO-11006 for use in dermatologic and ophthalmologic applications.
How it Works
MARCKS can play an important role in the pathogenesis of ARDS, certain cancers, and other conditions underpinned by inflammation.
In healthy individuals, MARCKS is bound to PIP2, keeping PIP2 sequestered and inactive, to regulate motility and cell division.
In certain diseases, MARCKS becomes phosphorylated, allowing for PIP2 detachment which can activate other signaling molecules such as FAK, AKT, and PI3K.
Signaling molecules may enhance cell migration and proliferation in certain cancers or drive inflammatory processes in persons with ARDS and other conditions.
BIO-11006 is a novel MARCKS inhibitor that can selectively dephosphorylate and inactivate the MARCKS protein, inhibiting downstream signaling.
This changes cell morphology, stops cell division, and reduces inflammation.
Phase 2 clinical trials have been completed with BIO-11006 in ARDS, COPD, and NSCLC, supporting safety and efficacy in these potential indications.